Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983273 | 1.00 | TP53 (0.36) | TP53 | |
| SCHEMBL29372030 | 1.00 | TP53 (0.36) | TP53 | |
| SCHEMBL29727417 | 1.00 | TP53 (0.36) | TP53 | |
| SCHEMBL8135304 | 0.72 | — | — | |
| SCHEMBL14300983 | 0.72 | — | — | |
| SCHEMBL10072292 | 0.72 | — | — | |
| SCHEMBL18270956 | 0.70 | OR51E2 (0.40) | — | |
| SCHEMBL20531445 | 0.70 | OR51E2 (0.40) | — | |
| SCHEMBL2487276 | 0.70 | OR51E2 (0.40) | — | |
| SCHEMBL23819606 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051271-A | Methods for treating infectious diseases | 欣扬生医股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4522128-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | Suntec Medical, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20250069693-A1 | Biomarkers for Age | SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2025-02-27 | — | — | US | claimed |
| US-12165745-B2 | Biomarkers for age | Viome Life Sciences, Inc. (US) | 2024-12-10 | — | — | US | claimed |
| WO-2023220086-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-4103727-A2 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | claimed |
| EP-4219735-B1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | ABBOTT DIABETES CARE (US) | 2026-04-01 | — | — | EP | disclosed |
| CN-120051271-A | Methods for treating infectious diseases | 欣扬生医股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4538692-A2 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | Abbott Diabetes Care (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4522128-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | Suntec Medical, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-118483297-A | Method and apparatus for analyte detection using electrochemical biosensors | 雅培糖尿病护理公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-110799651-B | Method and apparatus for analyte detection using electrochemical biosensors | 雅培糖尿病护理公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4103727-A2 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| CN-115484867-A | Transducer, nanoparticle transducer apparatus and system, and related methods of use | 华盛顿大学 | 2022-12-16 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220260517-A1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | ABBOTT DIABETES CARE INC. | 2022-08-18 | — | — | US | disclosed |
| EP-2825624-B2 | WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHOD OF MAKING SAME | MONOSOL LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-2838811-B2 | POWDERED POUCH AND METHOD OF MAKING SAME | MONOSOL LLC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11371957-B2 | Method and apparatus for analyte detection using an electrochemical biosensor | ABBOTT DIABETES CARE INC. (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | CD14, PML, SARS1 | TP53 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.